IART on XNAS, Health Care, Integra LifeSciences Holdings, job postings
Measures activity, not value. Not investment advice.
Short interest is 10% of shares while institutional holders rose 13% from the quarter before.
GoodFree cash flow of $85.8M over 12 months against $13M net income
WatchCapital spending fell 32% to $10.2M in the latest quarter
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $411.2M, net income $14.9M.
31 Dec 2021RevenueNet incomeNet losstallest bar $484.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$411.2M
$14.9M
30 Jun 2026
$418.8M
$4.5M
31 Mar 2026
$391.9M
-$4.6M
31 Dec 2025
$434.9M
-$1.7M
30 Sep 2025
$402.1M
-$5.4M
30 Jun 2025
$415.6M
-$484.1M
31 Mar 2025
$382.7M
-$25.3M
31 Dec 2024
$442.6M
$19.4M
30 Sep 2024
$380.8M
-$10.7M
30 Jun 2024
$418.2M
-$12.4M
31 Mar 2024
$368.9M
-$3.3M
31 Dec 2023
$397.0M
$19.8M
30 Sep 2023
$382.4M
$19.5M
30 Jun 2023
$381.3M
$4.2M
31 Mar 2023
$380.8M
$24.2M
31 Dec 2022
$398.0M
$52.9M
30 Sep 2022
$385.2M
$49.9M
30 Jun 2022
$397.8M
$44.8M
31 Mar 2022
$376.6M
$32.9M
31 Dec 2021
$405.5M
$45.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$1.7B
$1.6B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+0.8%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$13.0M
-$495.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$0.17
-$6.46
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
52.4%
52.3%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
4.4%
-29.3%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
0.8%
-30.1%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
1.2%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$85.8M
-$4.5M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$311.9M
$267.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
–
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
–
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
–
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$13.71
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
79.2
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
0.62
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.97
2.8
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+13%
233 13F filers vs 206
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
95%
74.0M shares held by 13F filers (30 Sep 2026) of 77.8M outstanding (22 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
10%
7.9M shares sold short (30 Oct 2026) of 77.8M outstanding (22 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
6.4
7.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
+7.9%
7.3M shares sold short in the report before, 7.9M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
79%
79% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 60%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+2.3%
$411.2M vs $402.1M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-32%
$10.2M vs $15.2M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$40K
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
65
the 12 months before: 0
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
13
13 articles in the last 7 days; its usual week has 2.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
5.2×
13 articles in the last 7 days; its usual week has 2.5.
Price $13.25 on 20 Nov 2026, +20% over 12 months (12-month range $8.90 to $19.85)
Sharp change
8-K and other filings
WARN layoff notice
Insider net buying (open market). Insiders bought a net $0 in the last 12 months (the 12 months before: -$39K).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 7 published in the last 12 months, +75% on the 12 months before.Revenue per quarter. Revenue $411.2M in the latest quarter, +2.3% on a year earlier.Capital spending per quarter. Capital spending $10.2M in the latest quarter, -32% on a year earlier.Institutional holders (13F filers). 233 13F filers reported holding it in the latest 13F quarter, +17% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months.Lobbying spend. Lobbying spend: $40K published in the last 12 months, -50% on the 12 months before.Workers in WARN layoff notices. Workers in WARN layoff notices: 65 published in the last 12 months (none in the 12 months before).
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source.
Quarter ended 31 Dec 2021: $405.5M, +4.3% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $376.6M, +4.6% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $397.8M, +2.0% on a year earlier; public on 28 Jul 2022
Quarter ended 30 Sep 2022: $385.2M, -0.4% on a year earlier; public on 27 Oct 2022
Quarter ended 31 Dec 2022: $398.0M, -1.8% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $380.8M, +1.1% on a year earlier; public on 27 Apr 2023
Quarter ended 30 Jun 2023: $381.3M, -4.2% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $382.4M, -0.7% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $397.0M, -0.2% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $368.9M, -3.1% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $418.2M, +9.7% on a year earlier; public on 30 Jul 2024
Quarter ended 30 Sep 2024: $380.8M, -0.4% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $442.6M, +11% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $382.7M, +3.7% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $415.6M, -0.6% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $402.1M, +5.6% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $434.9M, -1.7% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $391.9M, +2.4% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $418.8M, +0.8% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $411.2M, +2.3% on a year earlier; public on 24 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $27.4M, +225% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $9.3M, +40% on a year earlier; public on 28 Apr 2022
Quarter ended 30 Jun 2022: $9.4M, +42% on a year earlier; public on 28 Jul 2022
Quarter ended 30 Sep 2022: $9.2M, +26% on a year earlier; public on 27 Oct 2022
Quarter ended 31 Dec 2022: $14.5M, -47% on a year earlier; public on 23 Feb 2023
Quarter ended 31 Mar 2023: $13.7M, +47% on a year earlier; public on 27 Apr 2023
Quarter ended 30 Jun 2023: $15.5M, +65% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $13.1M, +43% on a year earlier; public on 26 Oct 2023
Quarter ended 31 Dec 2023: $24.5M, +70% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $15.5M, +13% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $29.7M, +91% on a year earlier; public on 30 Jul 2024
Quarter ended 30 Sep 2024: $29.6M, +127% on a year earlier; public on 5 Nov 2024
Quarter ended 31 Dec 2024: $29.6M, +21% on a year earlier; public on 26 Feb 2025
Quarter ended 31 Mar 2025: $28.9M, +87% on a year earlier; public on 6 May 2025
Quarter ended 30 Jun 2025: $20.1M, -32% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $15.2M, -49% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $17.2M, -42% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $14.8M, -49% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $12.3M, -39% on a year earlier; public on 30 Jul 2026
Quarter ended 30 Sep 2026: $10.2M, -32% on a year earlier; public on 24 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 250; public on 14 Feb 2022
31 Mar 2022 report: 257; public on 16 May 2022
30 Jun 2022 report: 259; public on 15 Aug 2022
30 Sep 2022 report: 253; public on 14 Nov 2022
31 Dec 2022 report: 253; public on 14 Feb 2023
31 Mar 2023 report: 257; public on 15 May 2023
30 Jun 2023 report: 252; public on 14 Aug 2023
30 Sep 2023 report: 236; public on 14 Nov 2023
31 Dec 2023 report: 266; public on 14 Feb 2024
31 Mar 2024 report: 268; public on 15 May 2024
30 Jun 2024 report: 224; public on 14 Aug 2024
30 Sep 2024 report: 216; public on 14 Nov 2024
31 Dec 2024 report: 216; public on 14 Feb 2025
31 Mar 2025 report: 210; public on 15 May 2025
30 Jun 2025 report: 199; public on 14 Aug 2025
30 Sep 2025 report: 200; public on 14 Nov 2025
31 Dec 2025 report: 198; public on 17 Feb 2026
31 Mar 2026 report: 195; public on 15 May 2026
30 Jun 2026 report: 206; public on 14 Aug 2026
30 Sep 2026 report: 233; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $5K published
Month from 1 Jan 2022: -$1K published
Month from 1 Mar 2022: -$3K published
Month from 1 Apr 2022: $10K published
Month from 1 May 2022: $16K published
Month from 1 Jul 2022: $19K published
Month from 1 Sep 2022: $454K published
Month from 1 Oct 2022: $392K published
Month from 1 Nov 2022: $5K published
Month from 1 Dec 2022: $12K published
Month from 1 Jan 2023: $43K published
Month from 1 Feb 2023: $209K published
Month from 1 Mar 2023: $16K published
Month from 1 Apr 2023: $250K published
Month from 1 Jul 2023: $79K published
Month from 1 Aug 2023: -$26K published
Month from 1 Sep 2023: $4K published
Month from 1 Oct 2023: $13K published
Month from 1 Nov 2023: $22K published
Month from 1 Dec 2023: $36K published
Month from 1 Jan 2024: -$150 published
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $40K published
Quarter from 1 Oct 2022: $40K published
Quarter from 1 Jan 2023: $40K published
Quarter from 1 Apr 2023: $40K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Apr 2024: $40K published
Quarter from 1 Jul 2024: $40K published
Quarter from 1 Oct 2024: $40K published
Quarter from 1 Jan 2025: $40K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Oct 2026: $40K published
Workers in WARN layoff notices
Month from 1 Mar 2026: 65 published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $102K (6 Nov 2025), higher than 93% of its own history.
Reported lobbying spend: $40K in Q3 2026, $40K in Q1 2025. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry.Health issues
Two or more unrelated kinds of records unusual within 30 days
30 Jul 2024confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Integra LifeSciences(IART): spent $29.7M on capital projects in the quarter ended 30 Jun 2024, 1.9× the same quarter last year, while it had 4.6M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year. Two unrelated kinds of activity within 140 days.
Short interest and volume: Short interest spike, became public on 27 Jun 2024
Financials: Quarterly capital spending jump, became public on 30 Jul 2024
Short interest and volume: Short interest spike, became public on 25 Jul 2024
Short interest and volume: Short interest spike, became public on 10 Aug 2024
Short interest and volume: Short interest spike, became public on 27 Aug 2024
Short interest and volume: Short interest spike, became public on 12 Sep 2024
Short interest and volume: Short interest spike, became public on 25 Sep 2024
Short interest and volume: Short interest spike, became public on 10 Oct 2024
Short interest and volume: Short interest spike, became public on 25 Oct 2024
Financials: Quarterly capital spending jump, became public on 5 Nov 2024
Short interest and volume: Short interest spike, became public on 13 Nov 2024
The quarter ended 30 Jun 2024 against the 8 quarters before it.
this quarterearliernormal: $14.1MSee the evidence (11 changes)
Short interest and volume: Short interest spike became public on 27 Jun 2024
Integra LifeSciences had 3.5M shares sold short in the 14 Jun 2024 report, 1.6× the same report last year.
This period
3.5M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
118K
How far from its usual level
+4.6
Same report last year
2.3M
History used
2,359 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 30 Jul 2024
Integra LifeSciences spent $29.7M on capital projects in the quarter ended 30 Jun 2024, 1.9× the same quarter last year.
This period
$29.7M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$14.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+7.4
Same quarter last year
$15.5M
History used
5,387 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $14.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 25 Jul 2024
Integra LifeSciences had 4.1M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
This period
4.1M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
109K
How far from its usual level
+7.0
Same report last year
2.0M
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Integra LifeSciences had 4.4M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.
This period
4.4M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
122K
How far from its usual level
+8.0
Same report last year
2.4M
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Integra LifeSciences had 4.8M shares sold short in the 15 Aug 2024 report, 1.7× the same report last year.
This period
4.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.4
Same report last year
2.8M
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Integra LifeSciences had 4.8M shares sold short in the 30 Aug 2024 report, 1.9× the same report last year.
This period
4.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.5
Same report last year
2.6M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Integra LifeSciences had 4.6M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.
This period
4.6M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
150K
How far from its usual level
+8.5
Same report last year
2.4M
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
Integra LifeSciences had 4.4M shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.
This period
4.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
230K
How far from its usual level
+5.6
Same report last year
2.5M
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
Integra LifeSciences had 5.1M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.
This period
5.1M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
300K
How far from its usual level
+5.9
Same report last year
2.4M
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 5 Nov 2024
Integra LifeSciences spent $29.6M on capital projects in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.
This period
$29.6M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$15.0M
Typical spread (median absolute deviation)
$1.6M
How far from its usual level
+6.3
Same quarter last year
$13.1M
History used
5,479 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $15.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 13 Nov 2024
Integra LifeSciences had 5.2M shares sold short in the 31 Oct 2024 report, 2.2× the same report last year.
This period
5.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
373K
How far from its usual level
+4.8
Same report last year
2.3M
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
11 Aug 2020confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Integra LifeSciences(IART): had 3.8M shares sold short in the 30 Jun 2020 report, 2.6× the same report last year, while it reported revenue of $258.7M for the quarter ended 30 Jun 2020, 33% below the same quarter last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 11 Jul 2020
Short interest and volume: Short interest spike, became public on 25 Jul 2020
Financials: Quarterly revenue change, became public on 11 Aug 2020
The 30 Jun 2020 report against the 24 reports before it.
this reportearliernormal: 1.4MSee the evidence (3 changes)
Short interest and volume: Short interest spike became public on 11 Jul 2020
Integra LifeSciences had 3.8M shares sold short in the 30 Jun 2020 report, 2.6× the same report last year.
This period
3.8M (the 30 Jun 2020 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
293K
How far from its usual level
+5.7
Same report last year
1.4M
History used
914 days
the 30 Jun 2020 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Jul 2020
Integra LifeSciences had 3.7M shares sold short in the 15 Jul 2020 report, 3.1× the same report last year.
This period
3.7M (the 15 Jul 2020 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
358K
How far from its usual level
+4.4
Same report last year
1.2M
History used
929 days
the 15 Jul 2020 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 11 Aug 2020
Integra LifeSciences reported revenue of $258.7M for the quarter ended 30 Jun 2020, 33% below the same quarter last year.
This period
$258.7M (the quarter ended 30 Jun 2020)
Normal quarter (median of 8 earlier)
$372.6M
Typical spread (median absolute deviation)
$10.8M
How far from its usual level
-3.1
Same quarter last year
$383.6M
History used
4,018 days
the quarter ended 30 Jun 20208 earlier quartersnormal: $372.6M
Fires when the period is at least 3.0 robust standard deviations away from the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 5.2M shares sold short in the 31 Oct 2024 report, 2.2× the same report last year.
Same report last year: 2.3M; its normal report is 2.5M.
See the evidence
This period
5.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
373K
How far from its usual level
+4.8
Same report last year
2.3M
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $29.6M on capital projects in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.
Same quarter last year: $13.1M; its normal quarter is $15.0M.
See the evidence
This period
$29.6M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$15.0M
Typical spread (median absolute deviation)
$1.6M
How far from its usual level
+6.3
Same quarter last year
$13.1M
History used
5,479 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $15.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 5.1M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.
Same report last year: 2.4M; its normal report is 2.5M.
See the evidence
This period
5.1M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
300K
How far from its usual level
+5.9
Same report last year
2.4M
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.
Same report last year: 2.5M; its normal report is 2.5M.
See the evidence
This period
4.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
230K
How far from its usual level
+5.6
Same report last year
2.5M
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.6M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.
Same report last year: 2.4M; its normal report is 2.5M.
See the evidence
This period
4.6M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
150K
How far from its usual level
+8.5
Same report last year
2.4M
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.8M shares sold short in the 30 Aug 2024 report, 1.9× the same report last year.
Same report last year: 2.6M; its normal report is 2.5M.
See the evidence
This period
4.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.5
Same report last year
2.6M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.8M shares sold short in the 15 Aug 2024 report, 1.7× the same report last year.
Same report last year: 2.8M; its normal report is 2.5M.
See the evidence
This period
4.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.4
Same report last year
2.8M
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.4M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.
Same report last year: 2.4M; its normal report is 2.4M.
See the evidence
This period
4.4M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
122K
How far from its usual level
+8.0
Same report last year
2.4M
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $29.7M on capital projects in the quarter ended 30 Jun 2024, 1.9× the same quarter last year, while it had 4.6M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year. Two unrelated kinds of activity within 140 days.
See the evidence (11 changes)
Short interest and volume: Short interest spike became public on 27 Jun 2024
Integra LifeSciences had 3.5M shares sold short in the 14 Jun 2024 report, 1.6× the same report last year.
This period
3.5M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
118K
How far from its usual level
+4.6
Same report last year
2.3M
History used
2,359 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 30 Jul 2024
Integra LifeSciences spent $29.7M on capital projects in the quarter ended 30 Jun 2024, 1.9× the same quarter last year.
This period
$29.7M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$14.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+7.4
Same quarter last year
$15.5M
History used
5,387 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $14.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 25 Jul 2024
Integra LifeSciences had 4.1M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
This period
4.1M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
109K
How far from its usual level
+7.0
Same report last year
2.0M
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Aug 2024
Integra LifeSciences had 4.4M shares sold short in the 31 Jul 2024 report, 1.8× the same report last year.
This period
4.4M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
122K
How far from its usual level
+8.0
Same report last year
2.4M
History used
2,406 days
the 31 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Aug 2024
Integra LifeSciences had 4.8M shares sold short in the 15 Aug 2024 report, 1.7× the same report last year.
This period
4.8M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.4
Same report last year
2.8M
History used
2,421 days
the 15 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Sep 2024
Integra LifeSciences had 4.8M shares sold short in the 30 Aug 2024 report, 1.9× the same report last year.
This period
4.8M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
146K
How far from its usual level
+9.5
Same report last year
2.6M
History used
2,436 days
the 30 Aug 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Sep 2024
Integra LifeSciences had 4.6M shares sold short in the 13 Sep 2024 report, 1.9× the same report last year.
This period
4.6M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
150K
How far from its usual level
+8.5
Same report last year
2.4M
History used
2,450 days
the 13 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2024
Integra LifeSciences had 4.4M shares sold short in the 30 Sep 2024 report, 1.7× the same report last year.
This period
4.4M (the 30 Sep 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
230K
How far from its usual level
+5.6
Same report last year
2.5M
History used
2,467 days
the 30 Sep 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Oct 2024
Integra LifeSciences had 5.1M shares sold short in the 15 Oct 2024 report, 2.1× the same report last year.
This period
5.1M (the 15 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
300K
How far from its usual level
+5.9
Same report last year
2.4M
History used
2,482 days
the 15 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 5 Nov 2024
Integra LifeSciences spent $29.6M on capital projects in the quarter ended 30 Sep 2024, 2.3× the same quarter last year.
This period
$29.6M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$15.0M
Typical spread (median absolute deviation)
$1.6M
How far from its usual level
+6.3
Same quarter last year
$13.1M
History used
5,479 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $15.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 13 Nov 2024
Integra LifeSciences had 5.2M shares sold short in the 31 Oct 2024 report, 2.2× the same report last year.
This period
5.2M (the 31 Oct 2024 report)
Normal report (median of 24 earlier)
2.5M
Typical spread (median absolute deviation)
373K
How far from its usual level
+4.8
Same report last year
2.3M
History used
2,498 days
the 31 Oct 2024 report24 earlier reportsnormal: 2.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
30 Jul 2024Financials change
spent $29.7M on capital projects in the quarter ended 30 Jun 2024, 1.9× the same quarter last year.
Same quarter last year: $15.5M; its normal quarter is $14.1M.
See the evidence
This period
$29.7M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$14.1M
Typical spread (median absolute deviation)
$1.4M
How far from its usual level
+7.4
Same quarter last year
$15.5M
History used
5,387 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $14.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 4.1M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.
Same report last year: 2.0M; its normal report is 2.4M.
See the evidence
This period
4.1M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
109K
How far from its usual level
+7.0
Same report last year
2.0M
History used
2,390 days
the 15 Jul 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 3.5M shares sold short in the 14 Jun 2024 report, 1.6× the same report last year.
Same report last year: 2.3M; its normal report is 2.4M.
See the evidence
This period
3.5M (the 14 Jun 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
118K
How far from its usual level
+4.6
Same report last year
2.3M
History used
2,359 days
the 14 Jun 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 4.0M shares sold short in the 31 May 2024 report, 1.8× the same report last year.
Same report last year: 2.3M; its normal report is 2.4M.
See the evidence
This period
4.0M (the 31 May 2024 report)
Normal report (median of 24 earlier)
2.4M
Typical spread (median absolute deviation)
118K
How far from its usual level
+6.6
Same report last year
2.3M
History used
2,345 days
the 31 May 2024 report24 earlier reportsnormal: 2.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.9M shares sold short in the 31 Jan 2023 report, 1.1× the same report last year.
Same report last year: 5.2M; its normal report is 4.2M.
See the evidence
This period
5.9M (the 31 Jan 2023 report)
Normal report (median of 24 earlier)
4.2M
Typical spread (median absolute deviation)
194K
How far from its usual level
+4.0
Same report last year
5.2M
History used
1,859 days
the 31 Jan 2023 report24 earlier reportsnormal: 4.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 108 entries; narrow the window or the kind of data to see older ones.
Not listed: 267 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000917520
Ticker
IART
Domain
integralife.com
Employer name
Integra Life Sciences, Integra LifeSciences Corporation (2 unverified)
Hq location
NJ|PRINCETON|08540 (1 unverified)
Lobbying client
derma sciences, integra lifesciences
Name
Acclarent, Inc, ACell, Inc, Arkis Biosciences Inc, Ascension Orthopedics Limited and 89 more
Uei
U84KB8BJRFF5
Wikipedia
Integra LifeSciences
DOL H-1B labor condition applications and PERM certifications151 data points9 Dec 2019 to 3 Aug 2026
Federal lobbying disclosures (LDA)10 records, 153 data points30 Jun 1999 to 30 Sep 2026
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records3 Feb 2016 to 23 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1199 data points31 Dec 2007 to 22 Oct 2026
SEC Form 4 insider transactions127 records, 432 data points6 Apr 2016 to 6 Nov 2025
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards7104 data points1 Oct 2007 to 28 Dec 2023
WARN layoff notices (state labor agencies)1 record, 3 data points26 Jan 2026 to 1 Feb 2026
Wikipedia pageviews11 data points11 Nov 2026 to 21 Nov 2026